Buybacks Continue Into October
Science Group (LSE:SAG), the AIM-quoted science and technology consultancy and systems group, has continued to repurchase its own shares, with transaction notices issued regularly through September and into October 2026, most recently on 9 October. The buyback activity follows interim results published on 27 July 2026, in which the company said it anticipated share repurchases in 2026 would exceed £20 million, subject to corporate activity. Those results showed higher adjusted operating profit and margins despite lower revenue.
What the Company Does
Science Group operates through several businesses. Its Services division, trading as Sagentia, provides consultancy across five practices: Medical, Innovation, Regulatory, Defence and Aviation. Its Systems activities include CMS2, which supplies submarine atmosphere systems, and Frontier, which develops radio and audio semiconductors. The group also owns freehold properties. Martyn Ratcliffe is executive chair.
Latest Developments
Total revenue for the six months to 30 June 2026 was £47.2 million, down from £57.2 million, partly because the prior period included pass-through defence revenue. Core revenue, excluding that pass-through element, was £46.4 million against £48.7 million. Adjusted operating profit edged up to £11.5 million from £11.3 million, lifting the margin to 24.3% from 19.7%.
Sagentia generated revenue of £29.0 million and adjusted operating profit of £7.0 million. CMS2 delivered revenue of £11.1 million with an unusually high margin of 38.3%, which the company attributed to contract timing and expects to normalise over the year. Frontier contributed revenue of £6.8 million and has launched its new Auria product. The group has appointed advisers to evaluate options for its freehold properties, which have an aggregate book value of £20.5 million.
Financial and Dividend Picture
Profit before tax was £8.1 million, compared with £32.2 million a year earlier, when results included a £24.0 million gain on the disposal of a corporate investment. Adjusted basic earnings per share rose to 20.4p from 19.3p. Cash conversion was 94%.
Group cash stood at £67.9 million and net funds at £56.8 million at 30 June, with a £30.0 million revolving credit facility from Lloyds Bank, running to March 2030, undrawn. During the half, the company bought back 2.4 million shares at an average of 553p, returning £13.5 million. At the end of June, 40.8 million shares were in issue and 5.4 million were held in treasury. A dividend of 10p per share for 2025, approved at the annual general meeting on 20 May 2026, was paid in July 2026. The corporate cost centre recorded an adjusted operating loss of £1.1 million, an improvement on the prior period.
Sector and Index Context
Science Group operates across healthcare, defence and technology markets, where demand for specialist consultancy can be cyclical but defence spending has been rising. Within the FTSE AIM All Share Index, it stands out as a cash-rich business with an active approach to capital allocation, combining acquisitions, buybacks and dividends.
Key Risks
Consultancy revenues depend on client R&D budgets, which can be cut in weaker conditions. Systems revenue can be lumpy because of contract timing, as the CMS2 margin shows. The company has described the geopolitical environment as volatile. Acquisitions, a core part of its strategy, carry integration and valuation risks.
What to Watch Next
The board expects sequential growth in the second half, led by Services, and said Sagentia Defence was already seeing improvement after the UK Defence Investment Plan was released in July 2026. Investors will watch the pace of buybacks, the outcome of the property review, and any acquisitions the board pursues with its cash resources.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...